Table.

Use of Prostate Specific Antigen–Based Prostate Cancer Screening^a

	Men Aged 66–74 y			Men Aged ≥75 y			Difference in Differences, Percentage Point Change (95% CI)b
	Before, % (Apr 2007– June 2008)	After, % (Oct 2008– Dec 2009)	Before-After Percentage Point Difference	Before, % (Apr 2007– June 2008)	After, % (Oct 2008– Dec 2009)	Before-After Percentage Point Difference
Overall	33.9	34.4	0.5	29.4	27.8	−1.6	−2.0 (−3.1 to −1.0)
Pre–USPSTF Recommendation Prostate Cancer Screening Rate Among Men Aged ≥75 y in HRR of Residence
Highest quartile	37.4	37.0	−0.4	35.4	32.4	−3.0	−2.7 (−4.8 to −0.5)
Middle quartiles	33.6	33.8	0.2	29.0	27.5	−1.5	−1.6 (−3.0 to −0.1)
Lowest quartile	31.1	32.9	1.8	24.4	24.1	−0.3	−2.0 (−4.0 to −0.1)
Urologist Density in HRR of Residence
Highest quartile	35.1	35.5	0.4	30.6	28.3	−2.3	−2.7 (−4.7 to −0.6)
Middle quartiles	34.4	34.2	−0.2	29.9	28.6	−1.3	−1.0 (−2.5 to 0.5)
Lowest quartile	31.7	33.5	1.8	27.2	25.7	−1.5	−3.3 (−5.3 to −1.3)

Abbreviations: HRR, hospital referral region; USPSTF, US Preventive Services Task Force.

^aThe Table presents use of prostate specific antigen–based screening among cancer-free men aged 66 to 74 years and 75 years and older residing in Surveillance, Epidemiology, and End Results program areas before and after the August 2008 USPSTF recommendation to discontinue prostate cancer screening among men 75 years and older and gives the differential changes in these outcomes, stratified by HRR-level prerecommendation screening rates and urologist density. The prerecommendation period was April 2007 to June 2008; the postrecommendation period was October 2008 to December 2009.

^bThe difference-in-differences estimates were adjusted for patient race and Elixhauser comorbidity score.